No Data
No Data
Nanjing Pharmaceutical (600713.SH) plans to distribute a dividend of 0.16 yuan per share in 2023, with ex-rights and ex-dividends on June 28.
Nanjing Pharmaceutical (600713.SH) announced that the company plans to distribute a cash dividend of 0.16 yuan per share for the 2023 fiscal year.
Nanjing Pharmaceutical Issues 500 Million Yuan Ultra-Short-Term Bonds
Nanjing Pharmaceutical (600713.SH) announced first-quarter results. Net profit of 1.59 yuan increased 6.65% year over year
Nanjing Pharmaceutical (600713.SH) released its report for the first quarter of 2024. The company achieved operating income of 1 during the reporting period...
NanJing Medical Plans to Issue Up to 6 Billion Yuan in Ultra Short-Term Bonds
[BT Financial Report Momentary Analysis] Nanjing Pharmaceutical's 2023 Quarterly Report: Asset Growth and Cash Flow Challenges Under Steady Operation
As an important participant in the pharmaceutical distribution industry, Nanjing Pharmaceutical Co., Ltd. (stock code: 600713) directly serves the national medical and health industry. The company's business covers the procurement, warehousing, management and sale of pharmaceuticals and medical equipment, and is supervised by various national departments such as the Ministry of Commerce. Within the industry, Nanjing Pharmaceutical not only actively participated in the activities of industry self-regulatory organizations, but also continued to contribute to the development of the pharmaceutical distribution field. In terms of assets and liabilities, Nanjing Pharmaceutical's 2023 three-quarter report shows that the company's total assets increased from 31,651 billion yuan at the end of the previous year to 33.203 billion yuan, an increase
Nanjing Pharmaceutical (600713.SH): Application to issue convertible bonds accepted by the Shanghai Stock Exchange
Gelonghui, January 18, 丨 Nanjing Pharmaceutical (600713.SH) announced that on January 17, 2024, the company received the “Notice on Accepting the Application for Issuance of Securities by Nanjing Pharmaceutical Co., Ltd. Shanghai Main Board Listed Company” (Shanghai Stock Exchange) (Shanghai Stock Exchange) [2024] No. 20) issued by the Shanghai Stock Exchange (hereinafter referred to as the “Shanghai Stock Exchange”). The Shanghai Stock Exchange checked the prospectus and related application documents submitted by the company for the issuance of securities by a company listed on the Shanghai Main Board. It believed that the application documents were complete and complied with the legal form, and decided to accept them and review them in accordance with the law.
No Data